AERI Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 lapkr. 2022 @ 23:00):

Stats
Šios dienos apimtis	1.22M
Vidutinė apimtis	786 842
Rinkos kapitalizacija	0.00
EPS	$-0.560 ( Q3 \| 2022-11-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0 (Sector) 42.63 (Industry) 30.78
ATR14	$0.0770 (0.50%)

AERI 0.00%

ALVO 1.33%

ALVOW 6.79%

BDSI -0.09%

BFRIW -5.93%

CLVRW 0.00%

CYTHW -4.35%

ENDP 0.00%

GRVI 7.61%

HPCO 0.06%

INDV -1.59%

JUPWW -20.00%

LFCR -0.19%

LNDC -3.52%

LSDI -23.29%

PRFX -3.65%

PROCW 10.09%

QLI 6.82%

SBFMW 0.00%

SHOT 9.43%

SHPH 4.28%

Insider Trading

Date	Person	Action	Amount	type
2022-11-21	Mchugh Julie	Sell	16 854	Stock Option (right to buy)
2022-11-21	Mcgraw Benjamin F Iii	Sell	16 854	Stock Option (right to buy)
2022-11-21	Mcdonnell Peter J	Sell	16 854	Stock Option (right to buy)
2022-11-21	Kopczynski Casey C.	Sell	65 941	Stock Option (right to buy)
2022-11-21	Lang Peter Frederick	Sell	160 551	Stock Option (right to buy)

INSIDER POWER
-99.57
Last 98 transactions
Buy: 1 757 162 \| Sell: 988 060

Tūris Koreliacija

Ilgas: 0.16 (neutral)

Trumpas: 0.47 (neutral)

Signal:(68.342) Neutral

Aerie Pharmaceuticals, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Aerie Pharmaceuticals, Koreliacija - Valiuta/Žaliavos

-0.81
( strong negative )

-0.94
( very strong negative )

-0.89
( strong negative )

-0.03
( neutral )

0.85
( strong )

0.70
( moderate )

Aerie Pharmaceuticals, Finansinės ataskaitos

Annual	2021
Pajamos:	$194.13M
Bruto pelnas:	$167.29M (86.17 %)
EPS:	$-1.610

FY	2021
Pajamos:	$194.13M
Bruto pelnas:	$167.29M (86.17 %)
EPS:	$-1.610

FY	2020
Pajamos:	$83.14M
Bruto pelnas:	$57.81M (69.53 %)
EPS:	$-3.99

FY	2019
Pajamos:	$69.89M
Bruto pelnas:	$65.06M (93.08 %)
EPS:	$-4.39

Financial Reports:

No articles found.

Aerie Pharmaceuticals, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Aerie Pharmaceuticals,

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.